Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 74587V107 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| Alan H. Auerbach 13D/A Amendment 6 | 16.0% |
10/6/2026
Event 10/4/2026
|
|
| Vanguard Group Inc 13G/A Amendment 11 | 0% |
3/27/2026
Event 3/13/2026
|
|
| BlackRock, Inc. 13G/A Amendment 1 | 5.6% |
4/17/2025
Event 3/31/2025
|
|
|
Camber Capital Management LP
13G/A
Amendment 5
|
0% |
2/14/2025
Event 12/31/2024
|
|
| Camber Capital Management LP | 0% | ||
| Stephen DuBois | 0% | ||
|
Acorn Bioventures, L.P.
13G/A
Amendment 3
|
8.0% |
2/14/2025
Event 12/31/2024
|
|
| Acorn Bioventures, L.P. | 3.3% | ||
| Acorn Bioventures 2, L.P. | 4.7% | ||
| Acorn Capital Advisors GP, LLC | 3.3% | ||
| Anders Hove | 8.0% | ||
| Acorn Capital Advisors GP 2, LLC | 4.7% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 1
|
0% |
2/14/2025
Event 12/31/2024
|
|
| Frazier Life Sciences Public Fund, L.P. | 0% | ||
| FHMLSP, L.P. | 0% | ||
| FHMLSP, L.L.C. | 0% | ||
| Frazier Life Sciences X, L.P. | 0% | ||
| FHMLS X, L.P. | 0% | ||
| FHMLS X, L.L.C. | 0% | ||
| Frazier Life Sciences XI, L.P. | 0% | ||
| FHMLS XI, L.P. | 0% | ||
| FHMLS XI, L.L.C. | 0% | ||
| James N. Topper | 0% | ||
| Patrick J. Heron | 0% | ||
| Albert Cha | 0% | ||
| James Brush | 0% | ||
| Daniel Estes | 0% | ||
|
Millennium Management LLC
13G/A
Amendment 3
|
3.9% |
2/3/2025
Event 12/31/2024
|
|
| Integrated Core Strategies (US) LLC | 2.8% | ||
| Millennium Management LLC | 3.9% | ||
| Millennium Group Management LLC | 3.9% | ||
| Israel A. Englander | 3.9% | ||
|
Acorn Bioventures, L.P.
13G/A
Amendment 2
|
6.7% |
11/14/2024
Event 9/30/2024
|
|
| Acorn Bioventures, L.P. | 2.8% | ||
| Acorn Bioventures 2, L.P. | 3.9% | ||
| Acorn Capital Advisors GP, LLC | 2.8% | ||
| Anders Hove | 6.7% | ||
| Acorn Capital Advisors GP 2, LLC | 3.9% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 2.98 k | $29.6 k |
| 2026 Q2 | 164 | 38.7 M | $314 M |
| 2026 Q1 | 159 | 37.9 M | $242 M |
| 2025 Q4 | 154 | 35.3 M | $210 M |
| 2025 Q3 | 137 | 34.4 M | $183 M |
| 2025 Q2 | 125 | 33.5 M | $115 M |
| 2025 Q1 | 120 | 30.4 M | $90.1 M |
| 2024 Q4 | 119 | 32.0 M | $102 M |
| 2024 Q3 | 106 | 29.8 M | $76.0 M |
| 2024 Q2 | 105 | 31.3 M | $102 M |
| 2024 Q1 | 105 | 31.0 M | $164 M |
| 2023 Q4 | 91 | 27.1 M | $117 M |
| 2023 Q3 | 76 | 25.7 M | $67.6 M |
| 2023 Q2 | 76 | 26.6 M | $93.8 M |
| 2023 Q1 | 84 | 27.9 M | $86.1 M |
| 2022 Q4 | 95 | 27.7 M | $117 M |
| 2022 Q3 | 89 | 27.7 M | $65.5 M |
| 2022 Q2 | 92 | 27.9 M | $79.5 M |
| 2022 Q1 | 109 | 29.9 M | $86.1 M |
| 2021 Q4 | 110 | 30.6 M | $93.1 M |
| 2021 Q3 | 122 | 32.2 M | $226 M |
| 2021 Q2 | 126 | 34.8 M | $319 M |
| 2021 Q1 | 124 | 36.6 M | $356 M |
| 2020 Q4 | 142 | 35.4 M | $364 M |
| 2020 Q3 | 144 | 38.7 M | $390 M |
| 2020 Q2 | 143 | 35.3 M | $368 M |
| 2020 Q1 | 144 | 39.0 M | $329 M |
| 2019 Q4 | 158 | 31.9 M | $279 M |
| 2019 Q3 | 164 | 36.6 M | $394 M |
| 2019 Q2 | 162 | 37.3 M | $474 M |
| 2019 Q1 | 179 | 34.2 M | $1.32 B |
| 2018 Q4 | 161 | 35.5 M | $723 M |
| 2018 Q3 | 183 | 37.1 M | $1.70 B |
| 2018 Q2 | 199 | 39.7 M | $2.20 B |
| 2018 Q1 | 195 | 35.9 M | $2.44 B |
| 2017 Q4 | 225 | 36.2 M | $3.61 B |
| 2017 Q3 | 196 | 36.7 M | $4.39 B |
| 2017 Q2 | 181 | 35.5 M | $3.10 B |
| 2017 Q1 | 159 | 38.8 M | $1.45 B |
| 2016 Q4 | 145 | 35.5 M | $1.09 B |
| 2016 Q3 | 168 | 30.0 M | $2.01 B |
| 2016 Q2 | 117 | 31.8 M | $948 M |
| 2016 Q1 | 132 | 30.4 M | $893 M |
| 2015 Q4 | 154 | 32.5 M | $2.55 B |
| 2015 Q3 | 182 | 30.7 M | $2.31 B |
| 2015 Q2 | 213 | 30.5 M | $3.55 B |
| 2015 Q1 | 215 | 29.1 M | $6.87 B |
| 2014 Q4 | 206 | 27.3 M | $5.18 B |
| 2014 Q3 | 202 | 26.9 M | $6.42 B |
| 2014 Q2 | 158 | 27.0 M | $1.78 B |
| 2014 Q1 | 142 | 25.1 M | $2.62 B |